Answers are grounded in this paper and cite their sources.
CONCLUSION: Three types of inner ear drug delivery systems (DDS) that were ready to be applied in clinics were developed. OBJECTIVES: To develop clinically applicable inner ear DDS for the treatment of inner ear disorders. METHODS: Inner ear DDS using clinically applicable materials were developed and evaluated. RESULTS: The systemic application of stealth-type nanoparticles encapsulating betamethasone provided superior therapeutic results for the treatment of noise-induced hearing loss compared with the systemic application of betamethasone in mice. Microparticles made of biodegradable polymer (poly (lactic/glycolic) acid, PLGA) encapsulating lidocaine were placed on the round window membrane of guinea pigs, and resulted in reasonable concentrations of lidocaine in the cochlea without serious adverse effects. The phase I/IIa clinical trial of the application of insulin-like growth factor-1 (IGF-1) in combination with gelatin hydrogel on the round window membrane was conducted, recruiting patients with acute sensorineural hearing loss after the failure of systemic application of steroids.
No takes yet. Share an insight, caveat, or question.
Sakamoto et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: